Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Villanueva

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Biomedicines|August 26, 2022
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune SystemDaniel Meraviglia-Crivelli, Angelina Zheleva, Martin Barainka, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2014
Idiotype vaccine production using hybridoma technologySusana Inoges, Ascensión López Díaz de Cerio, Helena Villanueva, et al.
Oncotarget|December 20, 2015
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapySandra Hervas-Stubbs, Mario M Soldevilla, Helena Villanueva, et al.
Molecular Therapy. Nucleic Acids|October 19, 2016
In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers BindingObdulia Rabal, Fernando Pastor, Helena Villanueva, et al.
World Journal of Clinical Oncology|July 21, 2011
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responsesSusana Inoges, Ascension Lopez-Diaz de Cerio, Helena Villanueva, et al.
Expert Review of Vaccines|June 23, 2011
Idiotype vaccines for lymphoma therapySusana Inogés, Ascensión López-Díaz de Cerio, Helena Villanueva, et al.
Methods in Cell Biology|February 22, 2026
Metastasis mouse model of breast cancer derived from circulating tumor cells (CTCs) after primary orthotopic tumor resectionÁngela Pérez-Cervera, Haritz Moreno, Helena Villanueva, et al.
Biomaterials|March 22, 2016
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapyTeresa Lozano, Mario Martínez Soldevilla, Noelia Casares, et al.
Expert Review of Vaccines|November 17, 2011
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphomaHelena Villanueva, Ascension Lopez-Diaz de Cerio, Susana Inoges, et al.
Iscience|February 2, 2026
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapyMartin Barainka, Angelina Zheleva, Angela Pérez-Cervera, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Biomedicines|August 26, 2022
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune SystemDaniel Meraviglia-Crivelli, Angelina Zheleva, Martin Barainka, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2014
Idiotype vaccine production using hybridoma technologySusana Inoges, Ascensión López Díaz de Cerio, Helena Villanueva, et al.
Oncotarget|December 20, 2015
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapySandra Hervas-Stubbs, Mario M Soldevilla, Helena Villanueva, et al.
Molecular Therapy. Nucleic Acids|October 19, 2016
In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers BindingObdulia Rabal, Fernando Pastor, Helena Villanueva, et al.
World Journal of Clinical Oncology|July 21, 2011
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responsesSusana Inoges, Ascension Lopez-Diaz de Cerio, Helena Villanueva, et al.
Expert Review of Vaccines|June 23, 2011
Idiotype vaccines for lymphoma therapySusana Inogés, Ascensión López-Díaz de Cerio, Helena Villanueva, et al.
Methods in Cell Biology|February 22, 2026
Metastasis mouse model of breast cancer derived from circulating tumor cells (CTCs) after primary orthotopic tumor resectionÁngela Pérez-Cervera, Haritz Moreno, Helena Villanueva, et al.
Biomaterials|March 22, 2016
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapyTeresa Lozano, Mario Martínez Soldevilla, Noelia Casares, et al.
Expert Review of Vaccines|November 17, 2011
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphomaHelena Villanueva, Ascension Lopez-Diaz de Cerio, Susana Inoges, et al.
Iscience|February 2, 2026
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapyMartin Barainka, Angelina Zheleva, Angela Pérez-Cervera, et al.
Pageof 3